News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
679,028 Results
Type
Article (38857)
Company Profile (247)
Press Release (639924)
Section
Business (203591)
Career Advice (1978)
Deals (35362)
Drug Delivery (78)
Drug Development (80771)
Employer Resources (167)
FDA (16010)
Job Trends (14781)
News (343895)
Policy (32420)
Tag
Academia (2531)
Africa (714)
Alliances (49022)
Alzheimer's disease (1139)
Approvals (15934)
Arizona (173)
Artificial intelligence (68)
Asia (36809)
Australia (5981)
Bankruptcy (350)
Best Places to Work (11256)
Biosimilars (63)
Biotechnology (173)
C2C Services and Suppliers (78812)
California (1786)
Canada (909)
Cancer (401)
Career advice (1648)
Cell therapy (113)
China (136)
Clinical research (63222)
Collaboration (129)
Colorado (71)
Compensation (74)
Connecticut (69)
COVID-19 (2499)
Cystic fibrosis (72)
Data (229)
Diabetes (79)
Diagnostics (5966)
Drug pricing (61)
Earnings (83640)
Employer resources (142)
Europe (78746)
Events (107782)
Executive appointments (137)
FDA (16207)
Florida (255)
Funding (135)
Gene therapy (88)
GLP-1 (506)
Government (4287)
Healthcare (18635)
Hotbed/Location (481143)
Illinois (247)
Indiana (144)
Infectious disease (2526)
Inflammatory bowel disease (88)
Interviews (307)
IPO (16197)
Job creations (3619)
Job search strategy (1413)
Kansas (94)
Layoffs (395)
Legal (7831)
Lung cancer (90)
Manufacturing (82)
Maryland (375)
Massachusetts (1461)
Medical device (13032)
Medtech (13037)
Mergers & acquisitions (19011)
Metabolic disorders (240)
Michigan (123)
Minnesota (212)
Neuroscience (1274)
New Jersey (540)
New York (561)
NextGen Class of 2024 (6483)
Non-profit (4456)
North Carolina (578)
Northern California (794)
Obesity (143)
Ohio (103)
Opinion (172)
Patents (66)
Pennsylvania (566)
People (55827)
Pharmaceutical (60)
Phase I (19621)
Phase II (27840)
Phase III (20792)
Pipeline (103)
Postmarket research (2548)
Preclinical (8327)
Press Release (64)
Rare diseases (127)
Real estate (5882)
Recruiting (63)
Regulatory (21179)
Research institute (2308)
Resumes & cover letters (346)
South America (1085)
Southern California (726)
Startups (3561)
Texas (222)
United States (8202)
Vaccines (474)
Washington State (244)
Weight loss (124)
Date
Today (6)
Last 7 days (659)
Last 30 days (2054)
Last 365 days (37153)
2024 (25700)
2023 (40102)
2022 (51215)
2021 (55765)
2020 (54132)
2019 (46563)
2018 (35035)
2017 (32136)
2016 (31505)
2015 (37571)
2014 (31336)
2013 (26363)
2012 (28586)
2011 (29276)
2010 (27344)
679,028 Results for "immunogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
May 14, 2024
·
9 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.
February 1, 2024
·
1 min read
Drug Development
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win
AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily pretreated patients with folate receptor-alpha-positive, platinum-sensitive ovarian cancer.
June 7, 2024
·
2 min read
·
Tristan Manalac
Deals
AbbVie Completes Acquisition of ImmunoGen
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
February 12, 2024
·
8 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
January 3, 2024
·
1 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.
December 20, 2023
·
2 min read
Deals
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
November 30, 2023
·
13 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of November 30, 2023, the grant of restricted stock units covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to twelve new employees.
December 1, 2023
·
1 min read
Policy
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Genprex, Inc. announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex’s lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.
March 12, 2024
·
7 min read
Drug Development
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
INmune Bio, Inc. is delighted to announce the successful completion of the extended stability validation for XPro TM continuous storage in solution at 2-8C.
April 23, 2024
·
5 min read
1 of 67,903
Next